Probi AB is a Swedish, publicly traded bioengineering company
The rapid growth of the probiotic segment and new exciting research on the importance of human microbiota have increased the interest from pharma companies, and their consumer healthcare divisions, in probiotic product development.
Probi has more than 25 years of experience in the successful development of clinically substantiated, health enhancing probiotics.
To further expand Probi's product development pipeline and commercialise its strain portfolio, Probi has signed a long-term development agreement with Cilag GmbH International, a member of the Johnson & Johnson family of companies.
The parties will jointly initiate a probiotic development programme.
The programme will be funded under non-disclosed financial terms by Cilag GmbH International and Probi will contribute with probiotic expertise.
“We are very happy to initiate this development programme together with a strong global partner in OTC."
"By combining Probi´s probiotic expertise with the pharma company's development resources and regulatory expertise, we will form a very strong team moving forward together,” says Ole Søgaard Andersen CEO of Probi.